OrthoXel is delighted to announce that following United States FDA 510k and CE mark clearance for the Apex Tibial Nailing System, the new Apex Femoral Nailing System has been granted European CE Mark, following the FDA 510(k) earlier in the year.
| CORK, Ireland, Nov. 20, 2018 /PRNewswire/ -- OrthoXel is a specialist orthopaedic trauma company, using innovative engineering design to evolve truly next generation fracture fixation devices. OrthoXel is delighted to announce that following United States FDA 510k and CE mark clearance for the Apex Tibial Nailing System, the new Apex Femoral Nailing System has been granted European CE Mark, following the FDA 510(k) earlier in the year. The Apex Femoral Nailing System has the potential to be implanted by the surgeon in antegrade (at the hip) and retrograde (at the knee) as a universal nail for left and right legs, dramatically reducing hospital inventory. Like the Apex Tibial Nailing System, the Apex Femoral Nailing System has the OrthoXel patented micromotion locking to stimulate bone callus formation. The new Apex Femoral Nailing System was showcased at the Orthopaedic Trauma Association meeting in Orlando, Florida in October and will be presented in the UK at the Orthopaedic Trauma Society annual meeting in Burton-on-Trent January 10-11th 2019. The Apex Femoral Nailing System The Apex Femoral Nailing System features a modern anatomic nail curvature in a universal nail that can be surgically implanted from antegrade or retrograde orientations with a dedicated instrumentation kit. The system offers a comprehensive suite of versatile multiple-trajectory locking options including patented OrthoXel™ micromotion for controlled axial movement with exceptional torsional stability to promote callus formation. Additional locking options include recon and rigid interlocking for unstable proximal femoral fractures. The unique Apex Femoral Nail locking options provide ultimate flexibility and control for the surgeon to choose the right fixation for each patient. In addition to patented gliding micromotion, the Apex system offers an innovative locking endcap that can simultaneously lock multiple bone screws for added stability when needed
Pat O’Connor Co-Founder & CEO, OrthoXel – “With this latest approval and ongoing clinical studies, OrthoXel is positioned to target the European and US markets throughout 2019 with products that we believe are a considerable advancement on predicate devices on the market. This is an exciting time for OrthoXel as we transition from R&D and proof of concept into commercialization of our unique devices.” Charles Daly Co-Founder & Chief Technical Officer, OrthoXel – “OrthoXel is delighted to receive European CE Mark for the Apex Femoral Nailing System for the specific treatment of a wide range of femoral fractures. We now have full regulatory approval for both our tibial and femoral nailing platforms and will focus on generating clinical case studies in order to be market ready for 2019. Our incredible engineering and design team in Cork has really strived to achieve truly next generation intramedullary nails that are packed with unique features and benefits for the surgeon and patient alike. We strongly recommend anyone that wants more detailed product information to visit our new website at www.orthoxel.com.” About OrthoXel OrthoXel is committed to patient-focused fracture care, offering surgeon-designed devices and an innovative approach to clinical evaluation, from initial concept designs through to full product launch. For more information about the technical specification and advanced locking options of the Apex Femoral and the Apex Tibial Nailing Systems visit: www.orthoxel.com/product Press Contact: Alanna Carty Global Marketing Manager 204965@email4pr.com, Tel: +353 (0) 86 274 1539
SOURCE OrthoXel |
View original content to download multimedia:
